Zentek Ltd. - ZTEK STOCK NEWS

Zentek (NASDAQ:ZTEK)(TSXV:ZEN) announced that its subsidiary, Albany Graphite (AGC), has achieved 99.99915% purity for a graphite sample from the Albany deposit. This ultra-high purity was attained using a two-step process without hydrofluoric acid. The material will be tested for lithium-ion battery anodes and evaluated for the nuclear market.

The company is exploring both graphite production and processing to create battery-ready anode material. An updated mineral resource estimate shows Indicated Mineral Resources of 22.9 million tonnes at 4.1% graphitic carbon and Inferred Mineral Resources of 13.1 million tonnes at 2.9% graphitic carbon. The Albany Graphite Project is located near infrastructure in Ontario, Canada, and has shown potential to compete with synthetic graphite in various applications.

Zentek (NASDAQ: ZTEK) has announced the grant of stock options to directors, officers, and employees. The grant includes a total of 1,935,000 common shares, priced at $1.52 per share, exercisable over the next five years.

For directors and officers, the options will vest in three installments: one third on the date of the grant, one third on the first anniversary, and one third on the second anniversary. Employees will see their options vest in four installments: one quarter on the date of the grant and one quarter annually thereafter.

Zentek has been granted a second patent by the Canadian Intellectual Property Office for its Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites, recognized as a broad-spectrum antimicrobial agent.

The patent includes 64 successful claims and covers the compound's use against bacteria, fungi, and viruses in various forms such as liquid, powder, and ointments. Zentek has also applied for this patent with the U.S. Patent and Trademark Office.

GO-Ag+ has shown higher cytotoxicity against bacteria than human cells and is being studied for its effectiveness in preventing and eliminating biofilms, a significant challenge in wound care and medical devices. The patent supports further development of GO-Ag+-based products for medical and veterinary markets.

CEO Greg Fenton emphasized that this milestone is important for Zentek's intellectual property commercialization strategy and aims to maximize shareholder value.

Zentek has signed a distribution agreement with DCL Supply for ZenGUARD Enhanced Air Filters, effective from March 19th, 2024, with an initial term of one year, automatically renewing annually unless terminated with 90 days' notice. These filters aim to improve indoor air quality without significantly increasing energy consumption or emissions. The agreement is pending Health Canada's registration under the Pest Control Products Act, allowing DCL Supply to distribute the filters across Canada upon approval.

DCL Supply, a reputable HVAC distributor with over 40 years of experience, will leverage its extensive network to deliver these innovative solutions. This partnership aims to address the growing need for efficient air filtration in industrial, commercial, and institutional settings, potentially reducing maintenance costs and improving health outcomes.

Zentek completed a case study on HVAC Total Cost of Ownership Savings for the City of Toronto, showcasing the benefits of using MERV 9A filters over MERV 13 filters. The study revealed annual cost savings of over $40 million, reduced carbon emissions, waste, and energy consumption. Zentek aims to provide property managers with a cost-effective, environmentally friendly solution to control infectious aerosols and keep people safe.

Zentek announces that its subsidiary, Triera Biosciences , has achieved positive results against avian influenza (H5N1) using multivalent aptamer technology. The development of a prophylaxis and therapeutic for highly pathogenic avian influenza has been prioritized, with promising initial test results. The binding affinity of the influenza aptamer is superior to that of the aptamer used for SARS-CoV-2, showing improved protection in animal models. The World Health Organization has labeled the current H5N1 outbreak as an 'enormous concern,' prompting governments worldwide to focus on combating the virus. Triera has filed a provisional patent on the influenza virus-targeting aptamer, aiming to develop assets to prevent further transmission of H5N1 and other infectious diseases.

Zentek announces board and management changes with the resignation of Dr. Francis Dubé as COO and Brian Bosse as a director, who has been appointed to the advisory board. The Company granted Mr. Bosse stock options for 40,000 shares at $1.42 per share.

Zentek provides an update on its ZenGUARD(TM) platform, focusing on the launch of Enhanced Air Filters for the HVAC market and new opportunities for surgical masks. The company's Business Development team is actively promoting ZenGUARD(TM) at industry events, including ASHRAE, AFS, and BUILDEX conferences, highlighting the benefits and technical details of the product. Zentek's efforts align with industry trends towards improved indoor air quality and higher MERV-rated filters to reduce disease transmission risks.

Zentek announces a distribution agreement with Medwell Solutions for ZenGUARDTM Enhanced Surgical Masks in the U.S., targeting the healthcare market.